BOSTON and LONDON, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the appointment of April Dovholuk and Ellie Im, MD to Centessa’s executive team as Senior Vice President of Development Operations and Senior Vice President of Clinical Development, Oncology, respectively.

波士顿和伦敦，2023年10月3日（GLOBE NEWSWIRE）-Centessa Pharmaceuticals plc（纳斯达克股票代码：CNTA），一家旨在发现和开发为患者转型的药物的临床阶段制药公司，今天宣布任命April Dovholuk和Ellie Im，医学博士分别担任Centessa执行团队的发展业务高级副总裁和肿瘤学临床开发高级副总裁。

In these newly created roles, Ms. Dovholuk will lead both Centessa’s global Clinical Trials and Development Operations teams, and Dr. Im will manage clinical development of the Company’s Oncology programs based on the LockBody® technology platform. “We are thrilled to welcome two new accomplished and experienced leaders to the Centessa executive team at this exciting juncture when we have SerpinPC in global registrational studies for the treatment of hemophilia B; LB101, our first LockBody candidate in a Phase 1/2a first-in-human trial for the treatment of solid tumors; and, ORX750, our development candidate for narcolepsy and other sleep/wake disorders in IND-enabling studies,” said Saurabh Saha MD PhD, Chief Executive Officer of Centessa.

在这些新创建的角色中，Dovholuk女士将领导Centessa的全球临床试验和开发运营团队，Im博士将基于LockBody®技术平台管理公司肿瘤学项目的临床开发。“当我们将SerpinPC用于治疗血友病B的全球注册研究时，我们很高兴欢迎两位新的有成就和经验丰富的领导者来到Centessa执行团队；LB101，我们在1/2a期的第一个锁体候选者用于治疗实体瘤的人体试验；以及ORX750，我们的发作性睡病和其他睡眠的发展候选者/Centessa首席执行官Saurabh Saha医学博士说。

“April has an impressive track record in global clinical trial strategy and execution across all stages of drug development. Ellie is a physician scientist and recognized leader in oncology clinical development and medical affairs. April and Ellie further strengthen the clinical and operational teams across our company and position us well as we look to advance current and future clinical programs across our portfolio.” Ms.

“April在药物开发的各个阶段的全球临床试验策略和执行方面都有令人印象深刻的记录.Ellie是一名医师科学家，也是肿瘤学临床开发和医疗事务的公认领导者.April和Ellie进一步加强了我们公司的临床和运营团队并对我们进行定位，我们希望推动当前和未来的临床进展横跨我们的产品组合。”太太

Dovholuk is an experienced global operational leader. Prior to joining Centessa, Ms. Dovholuk was Senior Vice President, Clinical Development Operations at Replimune where she.

Dovholuk是一位经验丰富的全球运营领导者。在加入Centessa之前，Dovholuk女士是Replimune临床开发业务的高级副总裁。